EXEL vs. HALO, RGEN, NVAX, CRL, NRC, MEDP, PGEN, LUNA, NBIX, and RVMD
Should you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Halozyme Therapeutics (HALO), Repligen (RGEN), Novavax (NVAX), Charles River Laboratories International (CRL), National Research (NRC), Medpace (MEDP), Precigen (PGEN), Luna Innovations (LUNA), Neurocrine Biosciences (NBIX), and Revolution Medicines (RVMD).
Exelixis (NASDAQ:EXEL) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.
Exelixis received 75 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 69.15% of users gave Halozyme Therapeutics an outperform vote while only 68.12% of users gave Exelixis an outperform vote.
Halozyme Therapeutics has a net margin of 36.94% compared to Exelixis' net margin of 11.10%. Halozyme Therapeutics' return on equity of 225.71% beat Exelixis' return on equity.
Exelixis currently has a consensus target price of $26.13, suggesting a potential upside of 24.94%. Halozyme Therapeutics has a consensus target price of $53.14, suggesting a potential upside of 18.86%. Given Exelixis' higher probable upside, equities research analysts plainly believe Exelixis is more favorable than Halozyme Therapeutics.
85.3% of Exelixis shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.9% of Exelixis shares are owned by insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Exelixis has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
Halozyme Therapeutics has lower revenue, but higher earnings than Exelixis. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Exelixis had 6 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 12 mentions for Exelixis and 6 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.19 beat Exelixis' score of 0.76 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.
Summary
Halozyme Therapeutics beats Exelixis on 11 of the 18 factors compared between the two stocks.
Get Exelixis News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exelixis Competitors List
Related Companies and Tools
